Table 3.
CPV DNA titres calculated by the MGB probe assay in commercial and experimental vaccines
| Vaccine | Company/reference | Specificity | Reported titre (CCID50)/dose | Viral DNA titre/dose |
|---|---|---|---|---|
| Vanguard 7 | Pfizer Inc. | Type 2 | ≥107a | 4.43 × 1012 |
| Vanguard CPV | Pfizer Inc. | Type 2 | ≥107a | 6.09 × 1011 |
| Tetradog-CHPL | Merial Italia S.p.A. | Type 2 | ≥103b | 7.26 × 108 |
| Parvodog-P | Merial Italia S.p.A. | Type 2 | ≥103b | 5.52 × 108 |
| Primodog | Merial Italia S.p.A. | Type 2 | ≥105.5b | 1.90 × 108 |
| Eurican-CHPPI2-L | MERIAL Italia S.p.A. | Type 2 | ≥104.9b | 2.92 × 1010 |
| Duramune DA2LP + Pv | Fort Dodge Animal Health S.p.A. | Type 2 | >104.5a | 7.45 × 107 |
| Nobivac® CEPPi | Intervet Italia S.r.l. | Type 2 | ≥107a | 3.17 × 1010 |
| Nobivac® PARVO-c | Intervet Italia S.r.l. | Type 2 | ≥107a | 2.08 × 1010 |
| Nobivac® PUPPY CP | Intervet Italia S.r.l. | Type 2 | ≥107a | 2.44 × 1010 |
| Canigen CEPPi/L | Virbac S.r.l | Type 2 | >103a | 1.07 × 1010 |
| 17/80-ISS | Buonavoglia et al. (1983) | Type 2 | 107.8c | 6.58 × 1010 |
a
Cell lines used for determination of viral titres are not reported.
b
Titres calculated on feline cells.
c
Titres calculated on canine A-72 cells.